(VTRS) Viatris - NASDAQ
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 18.493m USD | Total Return: 92% in 12m
Avg Turnover: 142M
EPS Trend: -96.1%
Qual. Beats: 4
Rev. Trend: -90.3%
Qual. Beats: 4
Warnings
Interest Coverage Ratio 0.3 is critical
Below Avwap Earnings
Tailwinds
Rs Leader, Idiosyncratic Leader
Viatris Inc. is a global healthcare company specializing in the development and distribution of a diverse pharmaceutical portfolio, including branded drugs, generics, complex generics, and biosimilars. The company operates across four primary geographic segments: Developed Markets, Greater China, JANZ (Japan, Australia, and New Zealand), and Emerging Markets. Its product line features well-known legacy brands such as Lipitor, Norvasc, and Lyrica, alongside a pipeline of collaborative projects targeting biosimilars and long-acting injectables.
The pharmaceutical industry is characterized by high capital expenditures and a rigorous regulatory environment, where companies increasingly rely on biosimilars to offset revenue losses from patent expirations on original biologic drugs. Viatris utilizes a diversified business model, supplying oral solids and injectables to a broad client base including wholesalers, governments, and retail pharmacies to mitigate regional market volatility. For a deeper look into the companys fundamentals, consider reviewing the detailed metrics available on ValueRay.
- Divestiture of non-core business units accelerates debt reduction and share buybacks
- Expansion of complex generic pipeline offsets pricing erosion in legacy brands
- Regulatory approval of biosimilar Botox candidate impacts long-term revenue growth targets
- Currency fluctuations in emerging markets and China affect consolidated net sales
- Free cash flow generation supports dividend sustainability and strategic capital allocation
| Net Income: -296.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.17 > 1.0 |
| NWC/Revenue: 28.20% < 20% (prev 27.23%; Δ 0.97% < -1%) |
| CFO/TA 0.06 > 3% & CFO 2.17b > Net Income -296.5m |
| Net Debt (12.8b) to EBITDA (2.95b): 4.34 < 3 |
| Current Ratio: 1.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.18b) vs 12m ago -1.43% < -2% |
| Gross Margin: 34.40% > 18% (prev 36.85%; Δ -2.45% > 0.5%) |
| Asset Turnover: 38.67% > 50% (prev 37.25%; Δ 1.43% > 0%) |
| Interest Coverage Ratio: 0.29 > 6 (EBIT TTM 139.4m / Interest Expense TTM 475.9m) |
| A: 0.11 (Total Current Assets 10.9b - Total Current Liabilities 6.81b) / Total Assets 36.8b |
| B: -0.01 (Retained Earnings -211.9m / Total Assets 36.8b) |
| C: 0.00 (EBIT TTM 139.4m / Avg Total Assets 37.7b) |
| D: 0.66 (Book Value of Equity 14.7b / Total Liabilities 22.2b) |
| Altman-Z'' = 1.43 = BB |
| DSRI: 0.89 (Receivables 3.08b/3.39b, Revenue 14.6b/14.3b) |
| GMI: 1.07 (GM 36.85% / 34.40%) |
| AQI: 0.94 (AQ_t 0.63 / AQ_t-1 0.67) |
| SGI: 1.02 (Revenue 14.6b / 14.3b) |
| TATA: -0.07 (NI -296.5m - CFO 2.17b) / TA 36.8b) |
| Beneish M = -3.08 (Cap -4..+1) = AA |
As of June 14, 2026, the stock is trading at USD 16.48 with a total of 6,156,018 shares traded.
Over the past week, the price has changed by +3.78%,
over one month by -4.43%,
over three months by +22.88% and
over the past year by +92.03%.
Viatris has received a consensus analysts rating of 3.44. Therefore, it is recommended to hold VTRS.
- StrongBuy: 2
- Buy: 1
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 18.1 | 9.6% |
P/E Forward = 6.4392
P/S = 1.2699
P/B = 1.2613
P/EG = 0.1452
Revenue TTM = 14.6b USD
EBIT TTM = 139.4m USD
EBITDA TTM = 2.95b USD
Long Term Debt = 12.4b USD (from longTermDebt, last quarter)
Short Term Debt = 1.93b USD (from shortTermDebt, last quarter)
Debt = 14.6b USD (from shortLongTermDebtTotal, last quarter) + Leases 268.9m
Net Debt = 12.8b USD (calculated: Debt 14.6b - CCE 1.80b)
Enterprise Value = 31.3b USD (18.5b + Debt 14.6b - CCE 1.80b)
Interest Coverage Ratio = 0.29 (Ebit TTM 139.4m / Interest Expense TTM 475.9m)
EV/FCF = 18.31x (Enterprise Value 31.3b / FCF TTM 1.71b)
FCF Yield = 5.46% (FCF TTM 1.71b / Enterprise Value 31.3b)
FCF Margin = 11.74% (FCF TTM 1.71b / Revenue TTM 14.6b)
Net Margin = -2.04% (Net Income TTM -296.5m / Revenue TTM 14.6b)
Gross Margin = 34.40% ((Revenue TTM 14.6b - Cost of Revenue TTM 9.55b) / Revenue TTM)
Gross Margin QoQ = 32.90% (prev 30.63%)
Tobins Q-Ratio = 0.85 (Enterprise Value 31.3b / Total Assets 36.8b)
Interest Expense / Debt = 3.26% (Interest Expense 475.9m / Debt 14.6b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 110.1m (EBIT 139.4m * (1 - 21.00%))
Current Ratio = 1.60 (Total Current Assets 10.9b / Total Current Liabilities 6.81b)
Debt / Equity = 1.00 (Debt 14.6b / totalStockholderEquity, last quarter 14.7b)
Debt / EBITDA = 4.34 (Net Debt 12.8b / EBITDA 2.95b)
Debt / FCF = 7.49 (Net Debt 12.8b / FCF TTM 1.71b)
Total Stockholder Equity = 15.0b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.79% (Net Income -296.5m / Total Assets 36.8b)
RoE = -1.97% (Net Income TTM -296.5m / Total Stockholder Equity 15.0b)
RoCE = 0.51% (EBIT 139.4m / Capital Employed (Equity 15.0b + L.T.Debt 12.4b))
RoIC = 0.35% (NOPAT 110.1m / Invested Capital 31.2b)
WACC = 6.06% (E(18.5b)/V(33.1b) * Re(8.81%) + D(14.6b)/V(33.1b) * Rd(3.26%) * (1-Tc(0.21)))
Discount Rate = 8.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -64.44 | Cagr: -0.92%
[DCF] Terminal Value 74.35% ; FCFF base≈1.77b ; Y1≈1.66b ; Y5≈1.54b
[DCF] Fair Price = 9.90 (EV 24.3b - Net Debt 12.8b = Equity 11.5b / Shares 1.16b; r=8.35% [WACC [floored]]; 5y FCF grow -7.57% → 2.50% )
EPS Correlation: -96.10 | EPS CAGR: -9.72% | SUE: 2.61 | # QB: 4
Revenue Correlation: -90.27 | Revenue CAGR: -3.72% | SUE: 1.75 | # QB: 4
EPS current Quarter (2026-06-30): EPS=0.60 | Chg30d=-0.97% | Revisions=+0% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.64 | Chg30d=-4.56% | Revisions=-64% | Analysts=9
EPS current Year (2026-12-31): EPS=2.46 | Chg30d=+0.95% | Revisions=+17% | GrowthEPS=+4.6% | GrowthRev=+3.3%
EPS next Year (2027-12-31): EPS=2.68 | Chg30d=+0.50% | Revisions=-17% | GrowthEPS=+8.8% | GrowthRev=+2.0%
[Analyst] Revisions Ratio: -64%